ABSTRACT
The objective of this study was to evaluate the predictive role of CD21low B cells as markers of new digital ulcers in systemic sclerosis patients. Peripheral blood B cell subpopulations and clinical assessments have been evaluated in 74 systemic sclerosis patients at baseline and after a 12-month follow-up. After a 12-month follow-up, 23 (31.1%) systemic sclerosis patients developed new digital ulcers. The median percentage of CD21low B cells was significantly higher in patients with than without new digital ulcers [10.1 (4.3-13.6) versus 4.8 (3.5-7.4); p < 0.01]. The 10% cut-off shows good diagnostic accuracy [area under the curve (AUC) = 0.732, confidence interval (CI) = 0.587-0.878; P = 0.01]. Kaplan-Meier curves show a significantly reduced free survival from new digital ulcers in systemic sclerosis patients with CD21low B cells ≥ 10% (p < 0.0001). In multivariate analysis, CD21low B cells ≥ 10%, modified Rodnan skin score (mRSS) and systolic pulmonary arterial pressure (sPAP) are associated with the development of new digital ulcers. We hypothesize that CD21low B cells are a predictive marker of new digital ulcers in systemic sclerosis patients.
Subject(s)
B-Lymphocytes/immunology , Biomarkers/metabolism , Receptors, Complement 3d/metabolism , Scleroderma, Systemic/immunology , Scleroderma, Systemic/metabolism , Skin Ulcer/immunology , Skin Ulcer/metabolism , B-Lymphocytes/metabolism , Female , Humans , Male , Middle AgedABSTRACT
Epstein-Barr virus (EBV)-associated lymphoproliferative disorder may resemble nonspecific inflammation. We report 3 cases of immunosuppressed adult patients with small lymphocytic EBV ulcers in the skin and oral mucosa, characterized by a lack of atypical lymphocytic infiltration. All 3 cases were diagnosed in routine practice. For comparisons, cases of conventional Epstein-Barr virus-positive mucocutaneous ulcer (EBVMCU) were reviewed which were extracted from our pathology archives (n=11). The present patients were 2 females and 1 male, aged above 70 years. The primary disease was rheumatoid arthritis (n=2) and dermatitis herpetiformis (n=1). The main source of immunosuppression was prednisolone (n=2) and methotrexate (n=1). The ulcers were located in the oral cavity, buttock, and/or external genitalia. Histology evaluation revealed nonspecific lymphocytic infiltration. Epstein-Barr virus-encoded small RNA (EBER)-positive cells were small and coexpressed CD20. The number of EBER-positive cells ranged from 52 to 132/HPF, which was within the range of that observed in the reviewed conventional EBVMCUs (range, 48 to 1328; median, 121). All 3 cases regressed spontaneously or by the reduction of immunosuppressants. Although the present cases lacked cytologic atypia, those clinical course and loads of EBER-positive cells (>50/HPF) suggested EBV involvement. Current cases of EBVMCU with small lymphocytic infiltration underscore the need for EBER in situ hybridization when an etiology of ulcer with predominant lymphocytes in an immunosuppressed patient is unclear.
Subject(s)
Epstein-Barr Virus Infections/pathology , Herpesvirus 4, Human/pathogenicity , Lymphocytes/pathology , Mouth Mucosa/pathology , Opportunistic Infections/pathology , Oral Ulcer/pathology , Skin Ulcer/pathology , Aged , Epstein-Barr Virus Infections/immunology , Epstein-Barr Virus Infections/virology , Female , Herpesvirus 4, Human/immunology , Host-Pathogen Interactions , Humans , Immunocompromised Host , Immunosuppressive Agents/adverse effects , Lymphocytes/immunology , Lymphocytes/virology , Male , Mouth Mucosa/immunology , Mouth Mucosa/virology , Opportunistic Infections/immunology , Opportunistic Infections/virology , Oral Ulcer/immunology , Oral Ulcer/virology , Risk Factors , Skin Ulcer/immunology , Skin Ulcer/virology , Viral LoadSubject(s)
Escherichia coli Infections/immunology , Immunocompromised Host , Malacoplakia/immunology , Skin Ulcer/immunology , Stem Cell Transplantation/adverse effects , Aged , Allografts , Anal Canal/pathology , Escherichia coli Infections/pathology , Humans , Malacoplakia/pathology , Male , Myelodysplastic Syndromes/therapy , Skin Ulcer/pathology , Transplant RecipientsSubject(s)
Arthralgia/diagnosis , Autoantibodies/blood , Dermatomyositis/diagnosis , Interferon-Induced Helicase, IFIH1/immunology , Lung Diseases, Interstitial/diagnosis , Skin Ulcer/diagnosis , Antirheumatic Agents/therapeutic use , Arthralgia/drug therapy , Arthralgia/immunology , Biomarkers/blood , Dermatomyositis/drug therapy , Dermatomyositis/immunology , Female , Humans , Lung Diseases, Interstitial/drug therapy , Lung Diseases, Interstitial/immunology , Rituximab/therapeutic use , Skin Ulcer/drug therapy , Skin Ulcer/immunology , Young AdultSubject(s)
Colitis, Ulcerative/complications , Proctitis/complications , Skin Diseases, Vascular/diagnosis , Skin Ulcer/diagnosis , Colitis, Ulcerative/drug therapy , Colitis, Ulcerative/immunology , Female , Humans , Infusions, Intravenous , Middle Aged , Proctitis/drug therapy , Proctitis/immunology , Skin/cytology , Skin/immunology , Skin/pathology , Skin Diseases, Vascular/drug therapy , Skin Diseases, Vascular/immunology , Skin Ulcer/blood , Skin Ulcer/drug therapy , Skin Ulcer/immunology , Treatment Outcome , Ustekinumab/administration & dosageABSTRACT
OBJECTIVE: Monogenic Behçet's disease (BD)-like conditions are increasingly recognized and to date have been found to predominantly involve loss-of-function variants in TNFAIP3. This study was undertaken to identify genetic and pathobiologic mechanisms associated with a BD-like mucocutaneous ulcerative syndrome and neuromyelitis optica (NMO) occurring in 3 generations of an Irish family (n = 5 cases and 5 familial controls). METHODS: Whole-exome sequencing was used to identify potential pathogenic variants in affected family members and determine segregation between affected and unaffected individuals. Relative v-rel reticuloendotheliosis viral oncogene homolog A (RELA) expression in peripheral blood mononuclear cells was compared by Western blotting. Human epithelial and RelA-/- mouse fibroblast experimental systems were used to determine the molecular impact of the RELA truncation in response to tumor necrosis factor (TNF). NF-κB signaling, transcriptional activation, apoptosis, and cytokine production were compared between wild-type and truncated RELA in experimental systems and patient samples. RESULTS: A heterozygous cytosine deletion at position c.1459 in RELA was detected in affected family members. This mutation resulted in a frameshift p.His487ThrfsTer7, producing a truncated protein disrupting 2 transactivation domains. The truncated RELA protein lacks a full transactivation domain. The RELA protein variants were expressed at equal levels in peripheral mononuclear cells. RelA-/- mouse embryonic fibroblasts (MEFs) expressing recombinant human RELAp.His487ThrfsTer7 were compared to those expressing wild-type RELA; however, there was no difference in RELA nuclear translocation. In RelA-/- MEFs, expression of RELAp.His487ThrfsTer7 resulted in a 1.98-fold higher ratio of cleaved caspase 3 to caspase 3 induced by TNF compared to wild-type RELA (P = 0.036). CONCLUSION: Our data indicate that RELA loss-of-function mutations cause BD-like autoinflammation and NMO via impaired NF-κB signaling and increased apoptosis.
Subject(s)
Apoptosis/genetics , Behcet Syndrome/genetics , Cytokines/immunology , NF-kappa B/immunology , Neuromyelitis Optica/genetics , Transcription Factor RelA/genetics , Adolescent , Adult , Animals , Apoptosis/immunology , Behcet Syndrome/immunology , Child , Female , Fibroblasts , Frameshift Mutation , Humans , Ireland , Loss of Function Mutation , Male , Mice , Mice, Knockout , Mice, Transgenic , Neuromyelitis Optica/immunology , Oral Ulcer/genetics , Oral Ulcer/immunology , Pedigree , Skin Ulcer/genetics , Skin Ulcer/immunology , Transcription Factor RelA/immunology , White People , Young AdultABSTRACT
OBJECTIVE: Anti-Ro52 antibody often co-occurs with anti-Jo1 antibody in antisynthetase syndrome and their co-occurrence correlates with a more aggressive clinical phenotype and poorer prognosis. The strong association of anti-Ro52 antibody with anti-melanoma differentiation-associated protein-5 (anti-MDA5) antibody has been indicated in juvenile myositis. The aim of this study was to assess the clinical significance of anti-Ro52 antibody in a cohort of adult patients with anti-MDA5-positive clinically amyopathic dermatomyositis with interstitial lung disease (CADM-ILD). METHODS: We assessed a cohort of 83 consecutive patients with anti-MDA5-positive CADM-ILD. Anti-MDA5 antibodies and anti-Ro52 antibodies were detected in immunoblotting and semi-quantitatively analysed by densitometry. Clinical features and the 24 month survival were compared between anti-MDA5-positive patients with and without anti-Ro52 antibodies. RESULTS: Anti-Ro52 antibodies were found in 74.7% of anti-MDA5-positive CADM-ILD patients and were associated with an increased frequency of rapidly progressive interstitial lung disease (RP-ILD; 54.8% vs 23.8%; P = 0.014) and cutaneous ulcerations (27.4% vs 4.8%; P = 0.033). The cumulative 24 month survival rate tended to be lower in patients with anti-Ro52 antibodies than patients without (59.9% vs 85.7%; P = 0.051). The combination of anti-Ro52 antibody status and anti-MDA5 antibody levels further stratified patients' survival rates, showing that the survival rate of patients who were dual positive for anti-MDA5 antibody and anti-Ro52 antibody was significantly lower than patients with mild positive anti-MDA5 antibody alone (59.9% vs 100%; P = 0.019). CONCLUSION: Anti-Ro52 antibody is highly prevalent in anti-MDA5-positive CADM-ILD patients and their coexistence correlates with a subgroup of patients with more aggressive phenotypes. The combination of anti-MDA5 antibody levels and anti-Ro52 antibody status could help to predict patients' prognosis and guide risk-based therapy.
Subject(s)
Antibodies, Antinuclear/immunology , Dermatomyositis/immunology , Interferon-Induced Helicase, IFIH1/immunology , Lung Diseases, Interstitial/immunology , Skin Ulcer/immunology , Adult , Autoantibodies/immunology , Dermatomyositis/drug therapy , Dermatomyositis/physiopathology , Disease Progression , Female , Humans , Immunosuppressive Agents/therapeutic use , Lung Diseases, Interstitial/drug therapy , Lung Diseases, Interstitial/physiopathology , Male , Middle Aged , Prognosis , Skin Ulcer/physiopathology , Survival RateABSTRACT
Behçet's disease (BD) is a heterogeneous multi-organ disorder in search of a unified pathophysiological theory and classification. The disease frequently has overlapping features resembling other disease clusters, such as vasculitides, spondyloarthritides and thrombophilias with similar genetic risk variants, namely HLA-B*51, ERAP1, IL-10, IL-23R. Many of the BD manifestations, such as unprovoked recurrent episodes of inflammation and increased expression of IL-1, IL-6 and TNFα, overlap with those of the hereditary monogenic autoinflammatory syndromes, positioning BD at the crossroads between autoimmune and autoinflammatory syndromes. BD-like disease associates with various inborn errors of immunity, including familial Mediterranean fever, conditions related to dysregulated NF-κB activation (eg TNFAIP3, NFKB1, OTULIN, RELA, IKBKG) and either constitutional trisomy 8 or acquired trisomy 8 in myelodysplastic syndromes. We review here the recent advances in the immunopathology of BD, BD-like diseases and the NF-κB pathway suggesting new elements in the elusive BD etiopathogenesis.
Subject(s)
Behcet Syndrome/immunology , Chromosomes, Human, Pair 8/immunology , NF-kappa B/immunology , Trisomy/immunology , Behcet Syndrome/genetics , Behcet Syndrome/pathology , Chromosomes, Human, Pair 8/genetics , Genetic Predisposition to Disease/genetics , Humans , Interleukin-10/genetics , Interleukin-10/immunology , Mouth Mucosa/immunology , Mouth Mucosa/metabolism , Mouth Mucosa/pathology , NF-kappa B/genetics , NF-kappa B/metabolism , Phenotype , Skin Ulcer/genetics , Skin Ulcer/immunology , Skin Ulcer/pathology , Trisomy/geneticsABSTRACT
In recent years, several studies suggested that the ability of hyperbaric oxygen therapy (HBOT) to promote healing in patients with diabetic ulcers and chronic wounds is due to the reduction of inflammatory cytokines and to a significant decrease in neutrophils recruitment to the damaged area. α4 and ß2 integrins are receptors mediating the neutrophil adhesion to the endothelium and the comprehension of the effects of hyperbaric oxygenation on their expression and functions in neutrophils could be of great importance for the design of novel therapeutic protocols focused on anti-inflammatory agents. In this study, the α4 and ß2 integrins' expression and functions have been evaluated in human primary neutrophils obtained from patients with chronic non-healing wounds and undergoing a prolonged HBOT (150 kPa per 90 minutes). The effect of a peptidomimetic α4ß1 integrin antagonist has been also analyzed under these conditions. A statistically significant decrease (68%) in ß2 integrin expression on neutrophils was observed during the treatment with HBO and maintained one month after the last treatment, while α4 integrin levels remained unchanged. However, cell adhesion function of both neutrophilic integrins α4ß1 and ß2 was significantly reduced 70 and 67%, respectively), but α4ß1 integrin was still sensitive to antagonist inhibition in the presence of fibronectin, suggesting that a combined therapy between HBOT and integrin antagonists could have greater antinflammatory efficacy.
Subject(s)
Hyperbaric Oxygenation , Integrin alpha4beta1/antagonists & inhibitors , Neutrophils/immunology , Peptidomimetics/therapeutic use , Skin Ulcer/therapy , Aged , Aged, 80 and over , CD18 Antigens/analysis , CD18 Antigens/metabolism , Cell Adhesion/immunology , Chronic Disease/therapy , Combined Modality Therapy/methods , Female , Follow-Up Studies , Humans , Integrin alpha4beta1/analysis , Integrin alpha4beta1/metabolism , Male , Middle Aged , Neutrophil Infiltration , Neutrophils/metabolism , Peptidomimetics/pharmacology , Primary Cell Culture , Skin Ulcer/blood , Skin Ulcer/immunology , Skin Ulcer/pathology , Treatment Outcome , Wound Healing/drug effects , Wound Healing/immunologyABSTRACT
Chronic wounds present a unique therapeutic challenge to heal. Chronic wounds are colonized with bacteria and the presence of a biofilm that further inhibits the normal wound healing processes, and are locked into a very damaging proinflammatory response. The treatment of chronic wounds requires a coordinated approach, including debridement of devitalized tissue, minimizing bacteria and biofilm, control of inflammation, and the use of specialized dressings to address the specific aspects of the particular nonhealing ulcer.
Subject(s)
Diabetic Angiopathies/physiopathology , Skin Ulcer/physiopathology , Wound Healing/physiology , Anti-Infective Agents/therapeutic use , Biofilms/drug effects , Chronic Disease , Cytokines/physiology , Diabetic Angiopathies/immunology , Diabetic Angiopathies/therapy , Drug Resistance, Bacterial/physiology , Drug Therapy, Combination , Humans , Immunity, Cellular/physiology , Peptide Hydrolases/physiology , Skin Ulcer/immunology , Skin Ulcer/therapy , Wound Healing/immunology , Wound Infection/immunology , Wound Infection/physiopathology , Wound Infection/therapyABSTRACT
Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) is a unifocal mucosal or cutaneous ulcer that is histologically characterized by proliferating EBV-positive atypical B cells. While EBVMCU demonstrates a histology similar to that of EBV-positive diffuse large B-cell lymphoma (DLBCL), their clinical behavior differs. Thus, characterizing distinguishing features of EBVMCU and EBV-positive DLBCL is critical. To identify unique characteristics between EBVMCU and lymphoma, we analyzed the clinicopathological and genetic features of 34 Japanese patients with EBVMCU and compared them to those of 24 EBV-positive DLBCL patients and 25 EBV-negative DLBCL patients. All patients with EBVMCU had localized ulcerative lesions, and 31 patients (91%) were using immunosuppressants, such as methotrexate (MTX) or hydroxycarbamide. All patients that were followed up with exhibited good prognosis following immunosuppressant reduction or chemotherapy. In addition, 17 EBV-positive DLBCL patients, and 15 EBV-negative DLBCL patients, received chemotherapy (P < 0.001, P < 0.001, respectively). Our data showed that EBVMCU did not increase indicators associated with lymphoma prognosis, such as soluble interleukin 2 receptor (sIL-2R) and lactate dehydrogenase (LDH) compared to those in the EBV-positive DLBCL or EBV-negative DLBCL groups (sIL-2R, P < 0.001, P = 0.025; LDH, P = 0.018, P = 0.038, respectively). However, histologically, EBVMCU exhibited EBV-positive, variable-sized, atypical B-cell proliferation. Thus, EBVMCU was histologically classified as: (1) polymorphous; (2) large cell-rich; (3) classic Hodgkin lymphoma-like; and (4) mucosa-associated lymphoid tissue lymphoma-like. Moreover, genetic analysis showed that immunoglobin heavy chain (IGH) gene rearrangement did not differ significantly between EBVMCU and EBV-positive DLBCL (44% vs. 32%; P = 0.377), or between EBVMCU and EBV-negative DLBCL (44% vs. 58%; P = 0.280). Therefore, it is difficult to distinguish EBVMCU from EBV-positive DLBCL using only pathological and genetic findings, suggesting that clinical information is important in accurately distinguishing between EBVMCU and EBV-positive DLBCL.
Subject(s)
Epstein-Barr Virus Infections/pathology , Herpesvirus 4, Human/pathogenicity , Lymphoma, Large B-Cell, Diffuse/pathology , Oral Ulcer/pathology , Skin Ulcer/pathology , Aged , Aged, 80 and over , Biomarkers, Tumor/genetics , Diagnosis, Differential , Epstein-Barr Virus Infections/genetics , Epstein-Barr Virus Infections/immunology , Epstein-Barr Virus Infections/virology , Female , Gene Rearrangement , Genes, Immunoglobulin Heavy Chain , Genes, T-Cell Receptor , Herpesvirus 4, Human/immunology , Humans , Immunocompromised Host , Immunohistochemistry , Immunosuppressive Agents/adverse effects , In Situ Hybridization , Japan , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoma, Large B-Cell, Diffuse/immunology , Lymphoma, Large B-Cell, Diffuse/virology , Male , Middle Aged , Oral Ulcer/genetics , Oral Ulcer/immunology , Oral Ulcer/virology , Polymerase Chain Reaction , Predictive Value of Tests , Skin Ulcer/genetics , Skin Ulcer/immunology , Skin Ulcer/virologyABSTRACT
Staphylococcus aureus fatty acid kinase FakA is necessary for the incorporation of exogenous fatty acids into the lipid membrane. We previously demonstrated that the inactivation of fakA leads to decreased α-hemolysin (Hla) production but increased expression of the proteases SspAB and aureolysin in vitro, and that the ΔfakA mutant causes larger lesions than the wild type (WT) during murine skin infection. As expected, necrosis is Hla dependent in the presence or absence of FakA, as both hla and hla ΔfakA mutants are unable to cause necrosis of the skin. At day 4 postinfection, while the ΔfakA mutant maintains larger and more necrotic abscesses, bacterial numbers are similar to those of the WT, indicating the enhanced tissue damage of mice infected with the ΔfakA mutant is not due to an increase in bacterial burden. At this early stage of infection, skin infected with the ΔfakA mutant has decreased levels of proinflammatory cytokines, such as interleukin-17A (IL-17A) and IL-1α, compared to those of WT-infected skin. At a later stage of infection (day 7), abscess resolution and bacterial clearance are hindered in ΔfakA mutant-infected mice. The paradoxical findings of decreased Hla in vitro but increased necrosis in vivo led us to investigate the role of the proteases regulated by FakA. Utilizing Δaur and ΔsspAB mutants in both the WT and fakA mutant backgrounds, we found that the absence of these proteases in a fakA mutant reduced dermonecrosis to levels similar to those of the WT strain. These studies suggest that the overproduction of proteases is one factor contributing to the enhanced pathogenesis of the ΔfakA mutant during skin infection.
Subject(s)
Bacterial Proteins/immunology , Metalloendopeptidases/immunology , Phosphotransferases (Carboxyl Group Acceptor)/immunology , Serine Endopeptidases/immunology , Skin Ulcer/immunology , Staphylococcal Skin Infections/immunology , Staphylococcus aureus/pathogenicity , Animals , Bacterial Load , Bacterial Proteins/genetics , Bacterial Toxins/genetics , Bacterial Toxins/immunology , Chemokine CCL4/genetics , Chemokine CCL4/immunology , Female , Gene Expression Regulation , Hemolysin Proteins/genetics , Hemolysin Proteins/immunology , Host-Pathogen Interactions/genetics , Host-Pathogen Interactions/immunology , Interleukin-17/genetics , Interleukin-17/immunology , Interleukin-1alpha/genetics , Interleukin-1alpha/immunology , Interleukin-1beta/genetics , Interleukin-1beta/immunology , Interleukin-6/genetics , Interleukin-6/immunology , Metalloendopeptidases/deficiency , Metalloendopeptidases/genetics , Mice , Phosphotransferases (Carboxyl Group Acceptor)/deficiency , Phosphotransferases (Carboxyl Group Acceptor)/genetics , Serine Endopeptidases/deficiency , Serine Endopeptidases/genetics , Signal Transduction , Skin/immunology , Skin/microbiology , Skin/pathology , Skin Ulcer/genetics , Skin Ulcer/microbiology , Skin Ulcer/pathology , Staphylococcal Skin Infections/genetics , Staphylococcal Skin Infections/microbiology , Staphylococcal Skin Infections/pathology , Staphylococcus aureus/enzymology , Staphylococcus aureus/genetics , Staphylococcus aureus/immunology , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/immunology , Virulence Factors/genetics , Virulence Factors/immunologyABSTRACT
Abstract Cutaneous tuberculosis is a rare extrapulmonary manifestation of tuberculosis which, like disseminated tuberculosis, commonly occurs in immunocompromised patients. Poncet reactive arthritis is a seronegative arthritis affecting patients with extrapulmonary tuberculosis, which is uncommon even in endemic countries. We report a previously healthy 23-year-old male patient with watery diarrhea associated with erythematous ulcers on the lower limbs and oligoarthritis of the hands. Histopathological examination of the skin showed epithelioid granulomatous process with palisade granulomas and central caseous necrosis. AFB screening by Ziehl-Neelsen staining showed intact bacilli, the culture was positive for Mycobacterium tuberculosis, and colonoscopy revealed multiple shallow ulcers. Disseminated tuberculosis associated with reactive Poncet arthritis was diagnosed, with an improvement of the clinical and skin condition after appropriate treatment.
Subject(s)
Humans , Male , Young Adult , Tuberculosis, Cutaneous/immunology , Tuberculosis, Cutaneous/pathology , Immunocompromised Host , Arthritis, Reactive/immunology , Immunocompetence , Pyrazinamide/therapeutic use , Rifampin/therapeutic use , Skin Ulcer/immunology , Skin Ulcer/pathology , Skin Ulcer/drug therapy , Tuberculosis, Cutaneous/drug therapy , Treatment Outcome , Ethambutol/therapeutic use , Isoniazid/therapeutic use , Mycobacterium tuberculosis/isolation & purification , Antitubercular Agents/therapeutic useABSTRACT
Cutaneous tuberculosis is a rare extrapulmonary manifestation of tuberculosis which, like disseminated tuberculosis, commonly occurs in immunocompromised patients. Poncet reactive arthritis is a seronegative arthritis affecting patients with extrapulmonary tuberculosis, which is uncommon even in endemic countries. We report a previously healthy 23-year-old male patient with watery diarrhea associated with erythematous ulcers on the lower limbs and oligoarthritis of the hands. Histopathological examination of the skin showed epithelioid granulomatous process with palisade granulomas and central caseous necrosis. AFB screening by Ziehl-Neelsen staining showed intact bacilli, the culture was positive for Mycobacterium tuberculosis, and colonoscopy revealed multiple shallow ulcers. Disseminated tuberculosis associated with reactive Poncet arthritis was diagnosed, with an improvement of the clinical and skin condition after appropriate treatment.
Subject(s)
Arthritis, Reactive/immunology , Immunocompetence , Immunocompromised Host , Tuberculosis, Cutaneous/immunology , Tuberculosis, Cutaneous/pathology , Antitubercular Agents/therapeutic use , Ethambutol/therapeutic use , Humans , Isoniazid/therapeutic use , Male , Mycobacterium tuberculosis/isolation & purification , Pyrazinamide/therapeutic use , Rifampin/therapeutic use , Skin Ulcer/drug therapy , Skin Ulcer/immunology , Skin Ulcer/pathology , Treatment Outcome , Tuberculosis, Cutaneous/drug therapy , Young AdultSubject(s)
Agammaglobulinemia/immunology , Epstein-Barr Virus Infections/diagnosis , Herpesvirus 4, Human/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Skin Ulcer/diagnosis , Agammaglobulinemia/blood , Agammaglobulinemia/diagnosis , Agammaglobulinemia/drug therapy , Aged , Biopsy , Cyclophosphamide/therapeutic use , Drug Therapy, Combination/methods , Epstein-Barr Virus Infections/drug therapy , Epstein-Barr Virus Infections/immunology , Epstein-Barr Virus Infections/virology , Herpesvirus 4, Human/isolation & purification , Humans , Immunosuppressive Agents/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Male , Prednisolone , Skin/immunology , Skin/pathology , Skin Ulcer/drug therapy , Skin Ulcer/immunology , Skin Ulcer/virology , Treatment OutcomeABSTRACT
The obligate human pathogen Haemophilus ducreyi causes both cutaneous ulcers in children and sexually transmitted genital ulcers (chancroid) in adults. Pathogenesis is dependent on avoiding phagocytosis and exploiting the suppurative granuloma-like niche, which contains a myriad of innate immune cells and memory T cells. Despite this immune infiltrate, long-lived immune protection does not develop against repeated H. ducreyi infections-even with the same strain. Most of what we know about infectious skin diseases comes from naturally occurring infections and/or animal models; however, for H. ducreyi, this information comes from an experimental model of infection in human volunteers that was developed nearly three decades ago. The model mirrors the progression of natural disease and serves as a valuable tool to determine the composition of the immune cell infiltrate early in disease and to identify host and bacterial factors that are required for the establishment of infection and disease progression. Most recently, holistic investigation of the experimentally infected skin microenvironment using multiple "omics" techniques has revealed that non-canonical bacterial virulence factors, such as genes involved in central metabolism, may be relevant to disease progression. Thus, the immune system not only defends the host against H. ducreyi, but also dictates the nutrient availability for the invading bacteria, which must adapt their gene expression to exploit the inflammatory metabolic niche. These findings have broadened our view of the host-pathogen interaction network from considering only classical, effector-based virulence paradigms to include adaptations to the metabolic environment. How both host and bacterial factors interact to determine infection outcome is a current focus in the field. Here, we review what we have learned from experimental H. ducreyi infection about host-pathogen interactions, make comparisons to what is known for other skin pathogens, and discuss how novel technologies will deepen our understanding of this infection.
Subject(s)
Chancroid/microbiology , Haemophilus ducreyi/pathogenicity , Host-Pathogen Interactions/immunology , Skin Ulcer/microbiology , Antigen Presentation , Bacterial Proteins/physiology , Cathelicidins/physiology , Chancroid/immunology , Chancroid/pathology , Cytokines/metabolism , Defensins/physiology , Dendritic Cells/immunology , Double-Blind Method , Gene Expression Regulation, Bacterial , Haemophilus ducreyi/genetics , Haemophilus ducreyi/immunology , Humans , Lymphocyte Subsets/immunology , Macrophages/immunology , Metabolome , Mutation , Neutrophils/immunology , Nontherapeutic Human Experimentation , Phagocytosis , Skin Ulcer/immunology , Skin Ulcer/pathology , Transcriptome , Virulence Factors/immunologySubject(s)
Coinfection/diagnosis , Cytomegalovirus Infections/diagnosis , Herpes Genitalis/diagnosis , Polymerase Chain Reaction , Skin Ulcer/diagnosis , Aged , Antiviral Agents/therapeutic use , Biopsy , Coinfection/drug therapy , Coinfection/immunology , Coinfection/virology , Cytomegalovirus/genetics , Cytomegalovirus/immunology , Cytomegalovirus/isolation & purification , Cytomegalovirus Infections/drug therapy , Cytomegalovirus Infections/immunology , Cytomegalovirus Infections/virology , DNA, Viral/isolation & purification , Fatal Outcome , Female , Genitalia, Female/pathology , Genitalia, Female/virology , Genitalia, Male/pathology , Genitalia, Male/virology , Herpes Genitalis/drug therapy , Herpes Genitalis/immunology , Herpes Genitalis/virology , Humans , Immunocompromised Host , Male , Middle Aged , Simplexvirus/genetics , Simplexvirus/immunology , Simplexvirus/isolation & purification , Skin/pathology , Skin/virology , Skin Ulcer/drug therapy , Skin Ulcer/immunology , Skin Ulcer/virologyABSTRACT
Stimulator of interferon genes associated vasculopathy with onset in infancy (SAVI), caused by heterozygote gain-of-function mutations in TMEM173, is characterized by fever attacks with ulcerating cutaneous manifestations on cold-sensitive areas and interstitial lung disease. A six-month-old boy was admitted to our hospital with fever, cough, and rash on the external surface of both upper and lower extremities. Respiratory symptoms consistent with ILD developed and skin lesions evolved to eschar formation particularly on acral regions. Ultimately, diagnosis of SAVI was confirmed at the age of 10â¯months due to the high level of interferon-score and a heterozygous N154S mutation in TMEM173. Since systemic corticosteroid and ruxolitinib were not effective, baricitinib was initiated at the age of 15â¯months, resulting in alleviation of fever attacks, cutaneous manifestations and respiratory symptoms within 2â¯months. In conclusion, we reported an infant diagnosed with SAVI at the age of 10â¯months and treated with baricitinib.